The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Amgen; Amgen; Amgen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Honoraria - Amgen; Amgen; Amgen; Amgen; BTG; BTG; BTG; BTG; Lilly; Lilly; Lilly; Lilly; Medtronic; Medtronic; Medtronic; Medtronic; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Sanofi; Sanofi; Sanofi; Sanofi
Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.
 
Thomas H. Cartwright
No Relationships to Disclose
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
 
Pilar Garcia-Alfonso
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
 
Zdenĕk Linke
Honoraria - Roche; Roche; Roche; Roche
Consulting or Advisory Role - Merck; Merck; Merck; Merck; Sanofi; Sanofi; Sanofi; Sanofi
 
Ana Ruíz Casado
No Relationships to Disclose
 
Eduardo Polo Marques
Honoraria - Amgen; Amgen; Amgen; Amgen; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
 
Pascaline Picard
Other Relationship - Sanofi; Sanofi; Sanofi; Sanofi
 
Marina Celanovic
Employment - Sanofi; Sanofi; Sanofi; Sanofi
 
Arvind Rup Singh
Employment - Sanofi; Sanofi; Sanofi; Sanofi
 
Taylor Salinardi
Employment - Sanofi; Sanofi; Sanofi; Sanofi
 
Ian Chau
Honoraria - Lilly; Lilly; Lilly; Lilly
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Oncologie; Oncologie; Oncologie; Oncologie; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD